Asia Pacific Antifungal Drugs Market Size & Outlook
- Pharmaceuticals
- Infectious Disease Treatment
- Antifungal Drugs Market Outlook
- Infectious Disease Treatment
Global Market
Related Markets
Ask a question about the antifungal drugs market
Asia Pacific antifungal drugs market highlights
- The Asia Pacific antifungal drugs market generated a revenue of USD 3,832.6 million in 2025.
- The market is expected to grow at a CAGR of 5.7% from 2026 to 2033.
- In terms of segment, azoles was the largest revenue generating drug class in 2025.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 3,832.6 million |
| Market revenue in 2033 | USD 5,922.9 million |
| Growth rate | 5.7% (CAGR from 2026 to 2033) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 22.6% of the global antifungal drugs market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,922.9 million by 2033.
Large target population base in countries such as China and India. Rising demand for the treatment due to high disease prevalence in the region.
The changing structure of the market in this region due to the acquisition of local companies by multinational players.
Increasing disposable income in developing nations is expected to attract more key players. Increasing investment by major pharmaceutical companies in the region for R&D.
No credit card required*
Publish Date: Jan 13, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Enzon Pharmaceuticals Inc | View profile | 1 | 20 Commerce Drive, Suite 135, Cranford, NJ, United States, 07016 | www.enzon.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | www.gsk.com |
Asia Pacific Antifungal Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Antifungal Drugs Market Outlook will help companies and investors design strategic landscapes.
Azoles was the largest segment with a revenue share of 50.55% in 2025.
Horizon Databook has segmented the Asia Pacific antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2021 to 2033.
Large target population base in countries such as China and India. Rising demand for the treatment due to high disease prevalence in the region.
The changing structure of the market in this region due to the acquisition of local companies by multinational players.
Increasing disposable income in developing nations is expected to attract more key players. Increasing investment by major pharmaceutical companies in the region for R&D.
- Asia Pacific Antifungal Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Azoles
- Echinocandins
- Polyenes
- Allylamines
- Others
- Asia Pacific Antifungal Drugs Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Dermatophytosis
- Aspergillosis
- Candidiasis
- Others
- Asia Pacific Antifungal Drugs Market Dosage Form Outlook (Revenue, USD Million , 2021-2033)
- Oral Drugs
- Ointments
- Powders
- Others
- Asia Pacific Antifungal Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retails Pharmacies
- Others
Reasons to subscribe to Antifungal Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Antifungal Drugs Market Outlook databook
- Our clientele includes a mix of Antifungal Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Antifungal Drugs Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Antifungal Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Antifungal Drugs Market, 2021-2033 (US$M)
Asia Pacific antifungal drugs market statistics, by drug class, 2021-2033 (US$M)
